Premium
Pimecrolimus versus placebo in genital aphthous ulcers of Behcet’s disease: a randomized double‐blind controlled trial
Author(s) -
CHAMSDAVATCHI Cheyda,
BARIKBIN Behrooz,
SHAHRAM Farhad,
NADJI Abdolhadi,
MOGHADDASSI Maryam,
YOUSEFI Maryam,
DAVATCHI Fereydoun
Publication year - 2010
Publication title -
international journal of rheumatic diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.795
H-Index - 41
eISSN - 1756-185X
pISSN - 1756-1841
DOI - 10.1111/j.1756-185x.2010.01531.x
Subject(s) - pimecrolimus , medicine , placebo , sex organ , behcet's disease , dermatology , randomized controlled trial , surgery , gastroenterology , calcineurin , disease , transplantation , alternative medicine , pathology , biology , genetics
Background: Genital aphthous ulcers of Behcet’s disease (BD) are painful and usually resistant to local treatments. Pimecrolimus is an ascomycin macrolactam, used in inflammatory skin diseases. Objective: To discover if pimecrolimus can accelerate the healing of BD genital aphthous ulcers. Methods: Ninety patients with genital aphthous ulcers were enrolled. Only patients treated with colchicine alone were selected. All patients signed a written consent form. Patients were randomly assigned to pimecrolimus or placebo cream, applied twice daily for 1 week. The primary outcome was the healing period. Up to 7 days, it was considered as a positive result. Results were compared by chi‐square test. The mean healing time was compared by analysis of variance. Analyses were done both by the ‘intention‐to‐treat’ and ‘treatment‐completed’ methods. Results: Both groups were similar at the entry (gender, age, ulcer size, pain intensity and treatment delay). By intention‐to‐treat analysis, in the pimecrolimus group, 18 patients had positive and 27 negative results. In the control group, four had positive and 41 negative results. The difference was significant (χ 2 = 10.167, P = 0.001). By treatment‐completed analysis, with pimecrolimus, 18 patients had positive and 22 negative results. With placebo, four had positive, and 41 negative results. The difference was significant (χ 2 = 12.574, P = 0.0004). Comparison of mean healing time in the pimecrolimus versus placebo group, demonstrated a significant acceleration both in intention‐to‐treat analysis (10.7 vs. 20.7 days, F = 17.466, P < 0.0001) and treatment‐completed analysis (8.3 vs . 20.7 days, F = 29.289, P < 0.0001). Conclusion: Pimecrolimus is safe and efficient in the treatment of BD genital ulcers, by accelerating the healing process.